Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

PI: Dr.ssa Arsela Prelaj 

The aim of this trial is to obtain more information on the treatment of locally advanced or metastatic (spread to other parts of the body) Non-Small Cell Lung Cancer (NSCLC) with repotrectinib or crizotinib. Repotrectinib and crizotinib are part of a class of drugs called tyrosine kinase inhibitors (TKIs). 

This trial involves 2 treatment groups: 

• Group A: Repotrectinib  
• Group B: Crizotinib